Effect of capecitabine on breast cancer patients with different estrogen receptor status

Authors

  • Gang Xu Department of General Surgery, Zhejiang Hospital, City of Hangzhou, Zhejiang Province 310013, China.
  • Xin Lv Fourth Wards of General Surgery, Shengzhou People’s Hospital (The First Affiliated Hospital of Zhejiang University Shengzhou Branch), City of Shengzhou, Zhejiang Province 312400, China.
  • Ke Lu The First Surgical Department, The Affiliated Hangzhou Xixi Hospital of Zhejiang Chinese Medical University, City of Hangzhou, Zhejiang Province, 310023, China.
  • Ming Hai Shen The First Surgical Department, The Affiliated Hangzhou Xixi Hospital of Zhejiang Chinese Medical University, City of Hangzhou, Zhejiang Province, 310023, China.
  • Qing Hua Zhang The First Surgical Department, The Affiliated Hangzhou Xixi Hospital of Zhejiang Chinese Medical University, City of Hangzhou, Zhejiang Province, 310023, China.
  • Wan Neng Pan The First Surgical Department, The Affiliated Hangzhou Xixi Hospital of Zhejiang Chinese Medical University, City of Hangzhou, Zhejiang Province, 310023, China.

DOI:

https://doi.org/10.3329/bjp.v15i2.43522

Keywords:

Breast cancer, Capecitabine, Chemotherapy, Estrogen receptor

Abstract

This meta-analysis is to compare the efficacy of capecitabine versus non-capecitabine chemotherapy on breast cancer patients with different estrogen receptor (ER) status. We searched relevant literatures from EMBASE, PubMed and OVID library to analyze pathologic complete response rate (PCR), overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and time to disease progression (TTP). Eleven different studies were enrolled, which revealed that ER positive breast cancer patients who received treatment regimen containing capecitabine can effectively improve PFS, PCR, TTP. However, the difference between capecitabine-containing and non-capecitabine group has no significant for DFS, OS. ER negative breast cancer patients who received treatment regimen containing capecitabine can obviously improve DFS and TTP. However, there was no significant effect for PFS, PCR and OS. The results indicated that capecitabine in combination with other chemotherapy drugs for breast cancer is effective, which can delay the progression time in patients to some extent.

Downloads

Download data is not yet available.
Abstract
638
Download
451

Downloads

Published

2020-07-04

How to Cite

Xu, G., X. Lv, K. Lu, M. H. Shen, Q. H. Zhang, and W. N. Pan. “Effect of Capecitabine on Breast Cancer Patients With Different Estrogen Receptor Status”. Bangladesh Journal of Pharmacology, vol. 15, no. 2, July 2020, pp. 47-57, doi:10.3329/bjp.v15i2.43522.

Issue

Section

Meta-Analysis